OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina

Oxford, UK – 7 October 2025: OXB (LSE: OXB), a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, has acquired a state-of-the-art viral vector manufacturing facility in Durham, North Carolina, from RTP Operating, LLC, a subsidiary of National Resilience Holdco, Inc. The FDA-approved facility enhances OXB’s commercial-scale GMP capacity in the U.S., allowing the company to meet increasing client demand across North America.

The acquisition includes two operational GMP drug substance suites, a dedicated fill-finish suite, and additional GMP capacity that is expandable. With this facility, OXB aims to support late-stage programs and commercial launches for clients, particularly in the adeno-associated virus (AAV) sector. The site is part of North Carolina’s Research Triangle Park, known for its skilled workforce and industry networks.

OXB paid approximately $4.5 million (£3.4 million) for the acquisition, funded using existing cash. Integration planning has already begun, with key functions expected to be operational by the first quarter of 2026. The acquisition aligns with OXB’s strategy to enhance its CDMO network and supports its financial outlook, which remains unchanged despite the transaction.

• Why it matters:
  • This acquisition strengthens OXB’s capacity to serve both existing and new clients in the rapidly growing cell and gene therapy market.
  • Expanding manufacturing capabilities in the U.S. may improve OXB’s competitive positioning in the global market.
• The latest: Integration planning has commenced, and operations are expected to be fully functional by Q1 2026.